Variable | Estimate | Standard Error | T Value | P Value |
Intercept | 164.054 | 9.316 | 17.61 | < 0.0001 |
Gender (female vs. male) | -20.628 | 8.251 | -2.500 | 0.013 |
Geography | ||||
Midwest vs. Northeast | -27.978 | 10.763 | -2.60 | 0.010 |
West vs. Northeast | -27.710 | 11.456 | -2.42 | 0.016 |
South vs. Northeast | -10.709 | 9.959 | -1.08 | 0.282 |
Unknown vs. Northeast | 156.946 | 122.997 | 1.28 | 0.202 |
Prior regimen | ||||
Everolimus vs. sunitinib | 18.188 | 9.619 | 1.890 | 0.059 |
Pazopanib vs. sunitinib | -2.983 | 9.865 | -0.300 | 0.762 |
Temsirolimus vs. sunitinib | -31.320 | 14.791 | -2.120 | 0.034 |
Other vs. sunitinib | -46.400 | 16.075 | -2.890 | 0.004 |
Sorafenib vs. sunitinib | -3.385 | 19.412 | -0.170 | 0.862 |
Bevacizumab vs. sunitinib | -50.226 | 22.874 | -2.200 | 0.028 |
Baseline hypothyroidism treatment (yes vs. no) | 25.538 | 8.927 | 2.860 | 0.004 |